---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-025265"
form_type: "8-K"
ticker: "IDXG"
cik: "0001054102"
company_name: "INTERPACE BIOSCIENCES, INC."
filed_at: "2022-09-07T23:59:59+00:00"
generated_at: "2026-06-23T13:42:10.956523+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Interpace sells Pharma Services unit to Flagship for $7M; expects ~$5M annual cash flow improvement

## Summary
- Sold Pharma Solutions business to Flagship Biosciences for ~$7M cash at close (plus up to $2M earnout based on revenue).
- Transaction improves operating cash flow by nearly $5M annually, per CEO.
- Pro forma: six-month 2022 operating loss narrows from $5.8M to $2.9M after sale.
- Company becomes focused molecular diagnostics firm (PancraGEN, ThyGeNEXT, ThyraMIR, RespriDX, BarreGEN).
- Ampersand and BroadOak affiliates provided equity to Flagship; Ampersand holds ~4.7M shares of Interpace common via Series B.

## SEC filing metadata
- accession: 0001493152-22-025265
- form_type: 8-K
- ticker: IDXG
- cik: 0001054102
- company_name: INTERPACE BIOSCIENCES, INC.
- filed_at: 2022-09-07T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1054102/000149315222025265/0001493152-22-025265-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1054102/000149315222025265/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-025265
- JSON: https://secwatch.observer/filing/0001493152-22-025265.json
- Plain text: https://secwatch.observer/filing/0001493152-22-025265.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.